Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Georgetown University Wedgewood Pharmacy National Center for Research Resources (NCRR) |
---|---|
Information provided by: | Georgetown University |
ClinicalTrials.gov Identifier: | NCT00457886 |
The purpose of this study is to measure hormones in the blood known to affect the timing of delivery after a single injection of 17-P in order to help understand its mechanism of action in preventing preterm delivery.
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Serum Levels of Hormones Known to Affect Parturition in Patients Receiving 17 Alpha-Hydroxyprogesterone Caproate (17-P) for the Prevention of Preterm Delivery |
Estimated Enrollment: | 20 |
Study Start Date: | July 2005 |
Estimated Study Completion Date: | June 2007 |
A recent study by Meis and colleagues published in the New England Journal of Medicine in June 2003 demonstrated a 33% reduction in the rate of preterm delivery in patients with a previous history of preterm delivery who then used weekly 17-P injections in the subsequent pregnancy. This is a milestone in the prevention of preterm delivery and is the reason you have chosen to receive treatment with 17-P. However, how 17-P works to prevent preterm delivery is unclear. Knowledge of the mechanism of action of 17-P would help in selecting patients for treatment and may be useful in monitoring the efficacy of therapy. Studies have suggested that the timing of delivery depends on a type of placental clock, affected by levels of corticotropin-releasing hormone (CRH) and progesterone (P). CRH can be thought to act as an accelerator, and P as a brake. Serial injections of 17-P beginning in the second trimester of pregnancy may prevent preterm delivery by maintaining progesterone dominance, and be reflected in increased levels of progesterone and/or 17-P, or decreased levels of cortisol and/or CRH. These are the hormones that will be measured in this study.
Results of the study will be important whatever the outcome. If there is no measurable change in the hormones measured, this is important to know and investigation of other markers can be pursued. If there is a measurable change in the hormones measured, then this pilot study could serve to support a larger more definitive study, which could lead to very valuable information relating to the practical use of 17-P for the prevention of preterm delivery.
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Primary care clinic
Inclusion Criteria:
Exclusion Criteria:
United States, District of Columbia | |
Georgetown University Medical Center | |
Washington, District of Columbia, United States, 20007 |
Study Director: | John Queenan, MD | Georgetown University |
Study ID Numbers: | IRB 2005-142 |
Study First Received: | April 6, 2007 |
Last Updated: | June 30, 2009 |
ClinicalTrials.gov Identifier: | NCT00457886 History of Changes |
Health Authority: | United States: Institutional Review Board |
Estrogen Antagonists Estrogens Pregnancy Complications Progesterone Obstetric Labor, Premature Hormone Antagonists Caproate Estradiol valerate Obstetric Labor Complications Hormones, Hormone Substitutes, and Hormone Antagonists |
Estradiol 17 beta-cypionate Hormones Estradiol 17-alpha-hydroxy-progesterone caproate Estrogen Receptor Modulators Progestins Estradiol 3-benzoate Polyestradiol phosphate Premature Birth |
Estrogen Antagonists Pregnancy Complications Hormone Antagonists Obstetric Labor, Premature Physiological Effects of Drugs Obstetric Labor Complications Hormones, Hormone Substitutes, and Hormone Antagonists |
Hormones 17-alpha-hydroxy-progesterone caproate Pharmacologic Actions Estrogen Receptor Modulators Progestins Estradiol Antagonists Premature Birth |